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Abstract 
The study of the interaction between light and biological matter, called 
biophotonics, contributes to our understanding of biological systems - from 
subcellular compartments up to the human organ system. Herein, light is 
employed as a tool to understand delivery of novel photopharmaceutical and 
antimicrobial systems to bacteria, cells, and tissue.  
The first part of this thesis (papers I and II) focuses on production of toxic species 
via photoactivation of a compound, both in cells and tissue, using two photon 
excitation (2PE). 2PE studies using near infrared excitation (NIR) afford deeper 
light penetrations depths in tissue. Novel methods for fluorescence reporting were 
developed to monitor penetration and localization of compounds, and via spectral 
signal from Förster resonance energy transfer (FRET) to monitor release in real-
time. 
Nanoparticles are becoming increasingly interesting as drug delivery systems. 
Multiphoton microscopy (MPM) and spectral analysis were used to evaluate 
particles for potential dermal drug delivery in paper III. Inherently luminescent 
silica particles revealed the size-dependent penetration of the particles in skin by 
combining ex vivo diffusion studies with 3D imaging and 2PE spectral detection 
and analysis. 
The final part of this thesis (papers IV – VII) combines photoactivation with drug 
delivery systems to focus on the study and potential treatment of bacterial 
infections. Charge-functionalization of cyclodextrins (CDs) for optimal delivery 
to biofilms was evaluated. It was found that positively charged CDs better 
distribute in a Staphylococcus epidermidis biofilm environment. Eliminating 
biofilm cultures without the use of antibiotics is explored by applying 
phototherapy with NIR 2PE. It was demonstrated that curcumin, the active 
ingredient in turmeric, can be targeted to kill bacteria within 3D regions as small 
as 1 x 1 x 1 µm.  
Taken together, this work developed biophotonics approaches for studying 
delivery of photopharmaceutics and antimicrobials to biological systems through 
application of MPM, spectral imaging, photoactivation, and development of 
model systems. 
 
Keywords: Multiphoton microscopy, two photon excitation, super resolution 
microscopy, fluorescence imaging, drug delivery, nanoparticles, cyclodextrins, 
antibiotics, microbial biofilms, Staphylococcus, photodynamic inactivation 
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1 Introduction 
  
Light interaction with biological systems enables us to not only see within 
microscopically small organisms i.e. microscopy images of cells and bacteria, but 
also influence physiological mechanisms, and even treat disease through light 
application, such as the clinical treatment “photodynamic therapy (PDT)” [1, 2]. 
The beauty of light as a tool to image, characterize, and treat lies in the non-
invasive nature of light itself i.e. near-infrared light (NIR) to image deeper into 
tissue and the high precision and spatial control of light delivery [3-5]. In this 
thesis, light interaction with biology was used to aid in the development of new 
pharmaceutics and novel treatment within the framework of a European research 
consortium. In the Marie Curie International Training Network (ITN), 
“CyclonHIT,” my goal has been to characterize the photopharmaceutical 
compounds created by the network in biological systems, using non-invasive 
biophotonics analysis techniques. 
The photodynamic process applied in light therapy is a wide-reaching treatment 
modality in which light sources are used to excite and promote release of toxic 
compounds from an external or endogenous photoactivatable compound with the 
goal of treating disease [6]. This is well documented for cells and tumors [7], 
although current translational methods face challenges from damaging light 
sources such as UV and blue-light irradiation, as well as difficulties in 
pharmaceutical delivery [8]. Phototherapy for treatment of antimicrobial resistant 
infections is also a growing field in itself; antimicrobial resistance has been 
named one of the most important health threats of the 21st century by the World 
Health Organization [9]. Photodynamic inactivation of bacteria (PDI) is an 
attractive approach for treatment due to the ability to use photoactivatable 
compounds to overcome systemic drug side effects, resistance development, and 
long-term treatment plans of traditional antibiotic approaches [10, 11] . Similar 
restrictions apply to PDI; delivery of pharmaceuticals and novel antimicrobial 
systems is not only an obstacle in drug design, but also difficult to monitor or 
measure in live systems. 
The process by which photoactivatable and antimicrobial compounds are used for 
therapeutic treatments requires an understanding of the mechanistic process by 
which the compound reacts with its environment, e.g. where the compound 
localizes in the biological target (cells, bacteria, skin, etc), how it interacts with 
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the environment, and the mode of action or mechanism by which it acts as a toxic 
agent.  
Herein, photoactivatable compounds, both novel [12, 13] and natural [14, 15] 
were investigated using techniques of biophotonics. Non-invasive bioimaging, 
using two photon excitation (2PE) and spectral analysis enabled penetration, 
localization, and activity studies of the compounds in vitro and in real-time. 
The primary aim of this research was to develop and optimize light-based 
methods for studying photopharmaceuticals and new antimicrobial delivery 
systems, but the biological system being studied varies throughout the papers 
presented. The papers progress from studies in single cancer cells using already 
established PDT techniques (paper I), to multiphoton microscopy (MPM) 
imaging and spectral characterization within the more complex human skin 
system using novel luminescent and photoactivatable nanoparticles (papers II and 
III). In the final stages, PDT, MPM imaging, and spectral analysis were combined 
to present novel methods for understanding drug delivery in a complex 3D 
infectious bacterial system. Lastly, in paper VII, PDI techniques were applied to 
bacteria, and were shown to be effective using non-invasive NIR two photon 
excitation (2PE) against biofilms for the first time.  
The structure of this thesis is as follows: chapter 2 introduces the background 
needed to understand the biophotonics techniques applied in this research (2.1); 
from the fundamental rules of fluorescence and photoactivation to the microscopy 
tools applied. Chapter 2 also introduces the three primary pharmaceutical 
challenges addressed (2.2) with a focus on the global problem of antibiotic 
resistance, and difficulties surrounding pharmaceutical development. In chapter 
3 the scientific objectives of each paper are described by introducing the primary 
research question addressed. Chapter 4 establishes the methods used in papers I 
– VII. Following this, the highlights of each paper are presented in chapter 5, and 
chapter 6 and 7 give a brief conclusion of the primary findings of this work and 
an outlook on what more could be done in the future.  
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2 Background 
 
2.1 Biophotonics 
 
Light as a tool is an elegant, non-invasive option for scientific exploration of the 
nano- and microscopic-world. Exploitation of light for scientific research, 
photonics, applied to the study of biological systems, leads to the field of 
biophotonics [16]. This section covers fundamentals of light spectroscopy and 
microscopy and principles of light excitation for applied research and 
experimental treatments. 
 
2.1.1 Photoexcitation and fluorescence 
 
The process of photoexcitation and subsequent fluorescence emission is 
illustrated by the Jablonski diagram in figure 1. Fluorescence refers to the process 
by which certain molecules, fluorophores, absorb a photon of a specific energy 
from a lamp or laser light source, and go through a series of photochemical 
processes which in turn lead to emission of another photon of lower energy; this 
photon produces the fluorescent signal seen in spectroscopy or microscopy. 
Figure 1 demonstrates the molecular interactions onset by the absorption of 
photons, and different potential processes that can be taken by the molecule. 
Upon absorption, the molecule enters an excited singlet electronic state (S1 or S2). 
This excited state exists for a finite period (referred to as the excited state lifetime, 
τ), then the fluorophore loses energy through internal conversion; conformational 
changes and interactions with the surrounding environment aid in this loss of 
energy and relaxation to the lowest vibrational energy state of the excited state of 
the fluorophore. At this point, a photon can be released producing a fluorescent 
signal [17].  
Alternatively, the fluorophore can be quenched, a process in which the energy is 
lost through energy transfer, complex-formation, or collisions with other 
molecules or environment.  
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An additional photochemical process that can occur instead of fluorescence 
emission, is that of intersystem crossing (ISC), considered “forbidden” by the 
laws of quantum mechanics. Although ISC does still occur, it is unfavoured. 
During this process the molecule transitions between the singlet excited state to 
the triplet excited state (T1). From this excited triplet state, the molecule can go 
through non-radiative relaxation in which energy is lost through environmental 
interaction but no fluorescence signal is produced, or it can lose energy through 
phosphorescence. Phosphorescence is emission of light, through emission of a 
photon like fluorescence, but at a longer time scale. The increase in length of 
emission radiation is due to the unfavourable emission process from T1 back to 
the singlet ground state, again through ISC [17].  
Figure 1. Jablonski diagram demonstrating the basics of fluorescence. A fluorophore enters 
an excited state after absorption of a photon. Energy is lost, as heat dissipation, through 
collisions with the environment. The molecule then relaxes back to the ground state, during 
which a photon is released as fluorescence emission. 
2. Background 
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In one photon excitation, the peak fluorescence emission will be at a longer 
wavelength than the peak fluorescence excitation, due to the stokes shift. The 
stokes shift refers to the energy difference between the two peaks; due to the 
energy of the excited state fluorophore that is dissipated as heat to the surrounding 
solvent molecules through collisions with the excited state fluorophore; this 
energy lost occurs during the lifetime of the excited state of the molecule as it 
enters S1 (figure 2). 
 
Not all molecules will return to a relaxed excited state and emit fluorescence; 
some can undergo processes such as quenching (in which fluorescence is not 
emitted due to an alternate transfer of the excited state energy), förster resonance 
energy transfer (FRET), in which energy will be transferred to another molecule 
(described in 2.1.6), or other energy processes. 
Fluorescence is a principle theme in all work presented in this thesis; every 
project was based on the use of fluorescence emission from compounds – 
although capture, analysis, technique, and materials used for fluorescence signal 
vary from papers I-VII. 
 
Figure 2. Upon absorption a fluorophore emits fluorescence emission at a longer 
wavelength due to the stokes shift, in which energy is lost during the excited state lifetime 
of the molecule. In one photon microscopy, emission will always be at a lower energy 
(longer wavelength) than excitation. 
2. Background 
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2.1.2 Fluorescent dyes 
 
Many biological materials contain endogenous fluorescence, referred to as 
autofluorescence, in which biological structures naturally emit light due to 
absorbing properties of cell organelles, such as mitochondria and lysosomes. The 
most common molecules causing autofluorescence in cells are nicotinamide 
adenine dinucleotide phosphate (NADPH) and flavins, as well as fluorescent 
signal due to collagen and elastin in the extracellular matrix of cells [18, 19]. To 
visualize biological material that does not contain autofluorescent molecules, or 
does not have high enough natural emission to analyse spectral signal, an 
exogenous fluorescent dye can be added [20, 21].   
Three primary types of fluorescent dyes are used in this research; (i) Organic 
dyes, employed for tracking of compounds in biological systems – anthracene, 
rhodamine, and fluorescein were chemically linked to molecules and tracked in 
cells, bacteria, and skin in papers I, II, IV, and V. (ii) Molecular probes, used as 
indicators of cell health or for staining of lipids and derivatives, in bacterial 
studies in papers V – VII and (iii) Biological fluorophores, including green 
fluorescent protein (GFP), blue fluorescent protein (BFP), and red fluorescent 
protein (dsRED), which can be used to modify bacteria to inherently express 
fluorescence [22, 23]. 
The primary molecular probes used in this research were nucleic acid stains 
SYTO9 and Propidium Iodide (PI) (papers IV- VII). These dyes provided 
viability staining of bacterial cultures. SYTO9 is a cell-permeant stain that 
increases in fluorescence upon binding to nucleic acids of intact, living cells. PI 
is not permeant to live cells so it is used to detect “dead” (membrane 
compromised) cells [24]. The use of SYTO9 and PI combined is often referred to 
as a “LIVE/DEAD” staining. 
The lipophilic molecular probe FM4-64 was used in papers V- VII to selectively 
label the membrane of bacterial cells for detection of individual bacterial with 
high resolution microscopy. FM4-64 dyes are nontoxic to cells and non-
fluorescent when in aqueous media. Upon insertion into the membrane they 
present a deep-red fluorescence (emission maximum = 734 nm) [25]. 
 
2.1.3 Laser scanning fluorescence microscopy 
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Fluorescence microscopy provides an approach for studying living and fixed cells 
with high sensitivity, unique labelling, and specificity [26]. By exploiting 
fluorescence properties of materials and biological samples, visualization and 
analysis of biological systems, such as cells and subcellular compartments, and 
dynamic events therein, can be understood [27, 28]. In laser scanning 
fluorescence microscopy, the sample is illuminated at a small focal volume and 
scanned point-by-point, enabling detection of 3D volumes at higher resolution, 
with less overall light damage to the biological sample [29]. 
Illustrated in figure 3 is a schematic diagram of a confocal laser scanning 
fluorescent microscope (CLSM). A laser excitation source is used for 
illumination with a specific wavelength and is sent through an illumination 
pinhole. This light then reflects from the surface of a dichroic mirror and passes 
through the microscope objective, and is scanned across the sample in a defined 
focal plane [30].  
Fluorescence emission from the sample is collected by the microscope objective 
and passes through the dichroic mirror (the mirror works by reflecting the 
Figure 3. Schematic illustration of the fundamentals of a laser scanning confocal 
fluorescent microscope. Light emitted from the sample passes through a “pinhole” that 
blocks out-of-focus light, before being collected by the detector. Scanning of the excitation 
light across the sample enables collection of an image one point at a time. Redrawn from 
[30]. 
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excitation wavelength from the light source but transmitting the emission 
wavelength from the sample). The light emitted by points on the sample are 
focused as a confocal point at the detector pinhole aperture; the fluorescence 
emission that occurs above and below the focal plane is not confocal with the 
pinhole and thus not detected and does not contribute to the final image [31].  
A photomultiplier tube, tuned for different fluorescent wavelengths, amplifies the 
signal detected and is then converted to a digital signal for further processing in 
the specific software used for the system.  
Alternative to a CLSM, laser scanning fluorescence microscopy can be achieved 
without the use of excitation and emission pinhole apertures by employing a more 
focused excitation light point source, as will be described in the next section. 
 
2.1.4 Multiphoton microscopy 
 
Multiphoton microscopy (MPM) is a form of laser-scanning microscopy that uses 
a ‘nonlinear’ excitation process; in which the fluorescent signal produced is not 
linearly dependent on the intensity of incident light, in contrast to conventional 
optical imaging. In this research, two photon excitation / microscopy (2PE / 2PM) 
is primarily used for biological imaging so this section will focus on the 
fundamentals of 2PE, but it should be noted that other nonlinear imaging 
techniques are equally useful in this field, such as second harmonic generation 
(SHG), ideal for imaging collagen [32], or three photon excitation, which can 
image as deep at 700 µm into brain tissue [33].  
2PE takes advantage of two-photon absorption (TPA) as first described by Maria 
Goeppert-Mayer in 1931 [34], in which two photons of light are absorbed with 
lower energy than what would be required to excite a molecule with one photon 
absorption, illustrated in figure 4. The energy of a photon is inversely 
proportional to its wavelength; the two photons absorbed in a singular event must 
have wavelengths double of that required for traditional one-photon excitation 
(1PE). Emitted light produced by TPA is higher in energy than the excitation 
light, thus the ability to excite fluorescence at higher energy using lower energy 
near-infrared (NIR) light enables laser microscopy at a less damaging and higher-
penetrating optical window [4, 5, 35, 36].   
2. Background 
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MPM overcomes standard drawbacks of other traditional microscopy techniques 
such as photobleaching and phototoxicity [37], which at high laser power, is a 
problem in the imaging of live samples. Furthermore, MPM provides a significant 
advantage in the imaging of thick specimens, such as tissue, as excitation with 
NIR light enables further reach of the beam path due to reduced absorption of 
light and reduced scattering of excitation and emission photons [38]. 
2PE requires nearly simultaneous absorption of two photons. The probability of 
a TPA event is a quadratic function of the excitation intensity. Because of this 
quadratic relationship; 2PE occurs only at the focal point where the photon 
density is high enough for two photons to absorb in the same instant, thus 
producing localized excitation with no need of a pinhole to block background 
light. This can be seen illustrated in figure 5, where the primary differences in the 
optical setup of MPM versus confocal (as described in section 2.1.3) are shown. 
To perform MPM, specific adjustments to a standard optical configuration are 
required. MPM requires the use of a mode-locked laser; pulses generated from 
this laser are at a higher power, which can produce the required photon density 
Figure 4. Jablonski diagram of one-photon (1PE) and two-photon excitation (2PE). 1PE 
occurs upon absorption of a single photon. 2PE requires that two photons of lower energy 
are absorbed through an intermediate state.  A vibrational relaxation occurs from the higher 
energy level of the excited state to the lowest energy level prior to the fluorescence emission 
process. Fluorescence emission occurs at the same wavelength for both 1PE and 2PE. 
2. Background 
10 
 
for a 2PE [39]. Although overall, the average power output of the laser remains 
relatively low [40]. Objectives, used to focus the beam into the sample, with high 
numerical aperture (NA) are required for optimal collection efficiency; with 
water or oil immersion objectives being preferred [41]. 
MPM provides advantage in imaging of scattering biological samples due to the 
decreased absorption of longer wavelengths and reduced scattering of the sample, 
as demonstrated by MPM images vs. wide-field images of bacterial biofilms in 
figure 6. Reduce absorption by biological materials such as water and blood leads 
to deeper penetration depths in tissue [42]; for example, MPM has been used to 
image skin up to 200 µm in depth [43]. This technique has become a valuable 
Figure 5. (A) One-photon vs two-photon excitation demonstrated by liquid solution in a 
quartz cuvette. Photos kindly provided by Johan Borglin. (B) Simplified illustration of the 
fundamental configuration of a multiphoton microscope. 
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tool in the life sciences and can be seen applied to a variety of other optically 
dense material, including bacterial communities [44-48].  
 
2.1.5 Super resolution microscopy 
 
Imaging of subcellular localization within bacteria requires better spatial 
resolution than what is achievable by standard microscopy. The standard 
resolution limit of fluorescence microscopy has been set by the diffraction-
limited resolution theory by Ernst Abbe, shown below,  where NA is the objective 
numerical aperture and λ is wavelength of illumination, restricts resolution at 
ideal conditions to approximately 200-300 nm [49]. 
 
 
Abbe Resolutionx,y = λ / 2NA 
 
Super resolution microscopy is an umbrella term describing several new 
techniques that overcome the traditional diffraction barrier. Two techniques were 
explored in papers V-VII; super resolution structured illumination (SR-SIM) and 
Airyscan imaging (figure 7). These techniques were used to understand the 
subcellular localization of compounds within individual bacterial cells.  
Figure 6.  (A) Wide-field fluorescence microscopy image of SYTO9 stained S. epidermidis 
biofilm, (B) Two photon microscopy (TPM) image of SYTO9 stained S. epidermidis 
biofilm, collected in a 3D z-stack, z-slices reconstructed to show topological features from 
z view, (C) TPM image of SYTO9 stained S. epidermidis biofilm incubated with a blue-
fluorescent nanoparticle, collected in 3D z-stack, z-slices reconstructed to 3D boxed image 
to visualize the entire structure of biofilm community.  
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SR-SIM is a wide field technique in which a sinusoidal pattern of light is used to 
illuminate the sample; and Fourier transformations are used to transform 
information collected from imaging into mathematical functions which, through 
computation, can provide fine details in terms of frequencies. Further 
computation transforms these details to be visible in real space again, thus 
providing a super resolution image [50, 51]. This technique was used briefly 
using a commercial system with help from the Center for Cellular Imaging at 
Sahlgrenska Academy, but the technique itself was not explored in detail in this 
research. SR-SIM required longer imaging times and higher laser power than 
what was most suitable for the live biological samples used in this research, thus 
Airyscan imaging was used for the continuation of the work. 
Although the Airyscan technique does not reach the same resolution as the other 
super resolution techniques (i.e. PALM, STED, refer to [52] for a thorough 
review) the subcellular localization of a compound in bacteria could be measured, 
i.e. the technique was robust enough for the scientific questions in papers V – 
VII. To describe the Airyscan technique requires a short background in collection 
methods of confocal microscopy:  
In traditional confocal laser scanning microscopy, as described in section 2.1.3, a 
pinhole is placed to the image conjugated plan (figure 3 in 2.1.3); fluorescence 
emission light is sent through a pinhole, and the resultant diffraction pattern of 
the light is known as the “airy disk”, a bright central circular disk surrounded by 
rings with decreasing intensity at increasing distance (figure 7) [53].  
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Figure 7. (A) The point spread function, the diffraction pattern of light emitted from a point 
source, shown as an intensity distribution relative to the radius of the concentric rings of the 
diffraction pattern when viewed in the x-y plane, shown by the “airy disk.” (B) Illustration 
of the airyscan detection technique. The Airyscan detector array (5) is placed in a conjugate 
plane relative to the excitation spot, generated fluorescence is sent through an emission filter 
(2) and zoom optics (3) project a chosen number of airy unit (AU) orders; the resultant airy 
disk pattern (4) is projected onto the detector array where each of the detector elements acts 
as its own small pinhole with information of the point source position. Reprinted with 
permission from [54]. 
A 
B 
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With the use of a pinhole, the most intense central point of the airy disk is detected 
while the lower intensity outer regions are rejected, thus out-of-focus light 
emitted from the sample will be rejected and not imaged. 
A smaller pinhole results in higher resolution as the signal detected can be better 
localized to the point source emission (the fluorophore in the sample), but with a 
reduction in pinhole also comes a reduction in light detection efficiency, as less 
light will be collected through the pinhole. This leads to an increase in signal-to-
noise ratio, thus poorer quality images. Using the Airyscan technique, the 
traditional pinhole in confocal microscopy is replaced with a concentrically-
arranged hexagonal detector array consisting of 32 single detector elements each 
acting as a pinhole (figure 7). The confocal pinhole remains open so the entire 
airy disc is collected, while the signal collected by the individual detector 
elements is reconstructed (post-imaging) to produce an image [54].  
 
2.1.6 Förster resonance energy transfer 
 
Förster resonance energy transfer (FRET) is a process in which energy is 
transferred between a donor (D) molecule and an acceptor (A) molecule through 
non-radiative interaction. For FRET to occur, the emission spectrum of the donor 
molecule should overlap with the absorption spectrum of the acceptor molecule 
(figure 8), and D-A should be within a specific distance of each other. This 
distance is a distance known for specific FRET pairs of D-A, thus FRET signal 
can be used to calculate the distance between two known molecules [17]. The rate 
of FRET depends on the spectral overlap of D-A, quantum yield of the donor, and 
orientation of the D-A transition dipole. This technique has become valuable for 
the study of, for example, protein-protein interactions in cellular environments 
[55, 56].  
An important distinction in understanding FRET is that there is no photon 
emission involved in the resonance energy transfer described. Theoretically, 
FRET relies on the concept that an oscillating dipole can undergo energy 
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exchange with another dipole with similar resonance frequency, i.e. “coupled 
oscillators” [57].  
In experimentation, FRET can be described in rate of energy transfer (kT(r)), in 
which transfer rate is written as a function of the distance r between D-A, shown 
in equation 1.  
Figure 8. (A) A förster resonance energy transfer molecular pair (FRET) must have an 
overlap between donor emission and acceptor absorption spectra. (B) The energy transfer 
efficiency in a FRET process decreases with increasing distance between donor and 
acceptor molecule. 
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kT(r) = ( 1 / τD ) ( R0 / r )6                                                      (eqn 1) 
 
To calculate kT(r) with this equation the distance between D-A at which EFRET is 
at 50%, R0 (“Förster distance”), must be known, as well τD, the decay time of the 
donor in the absence of the acceptor. 
As energy transfer rate depends on the decay rate of the donor, energy transfer 
will be efficient if the transfer rate is much faster than decay rate. The efficiency 
of energy transfer (EFRET) is described by the fraction of photons absorbed by the 
donor that are transferred to the acceptor, given by equation 2. 
E = kT(r) / (τD -1 + kT(r))                                    (eqn 2) 
 
Combining equations 1 and 2 gives EFRET and demonstrates the dependence of 
transfer efficiency on the distance of D-A when the distance is near R0. 
 
E = R0
6 / (R0
6 + r6)                                      (eqn 3) 
In the experimental settings in this research (paper II), the exact distance of D-A 
was not measured, rather transfer efficiency was observed to qualitatively assess 
whether D-A remained linked or had separated. In this case, relative fluorescence 
intensity of the donor in absence of the acceptor (FD) and presence of acceptor 
(FDA) could be used (equation 4).  
E = 1 – (FDA /  FD)                                 (eqn 4) 
 
FRET signal by 2PE spectra and TPM imaging in human skin was performed in 
paper II.  
 
2.2 Pharmaceutical challenges 
 
In this section, the three major challenges in current medical research explored in 
this thesis are described: antimicrobial resistance, cancer and light therapy 
applied to skin cancer, and drug delivery to tissue.  
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2.2.1 Bacterial biofilms & antibiotic resistance 
 
Antibiotic resistance has become a global concern; the US Centers for Disease 
Control and Prevention (CDC) have declared multiple resistant bacteria to be an 
urgent threat with the emergence of resistant bacteria being declared a “crisis” 
[58]; the World Health Organization has named antibiotic resistance one of the 
most important threats of the 21st century [9]. The work presented in this thesis 
was performed under the framework of a Marie Curie ITN project with the focus 
“nanocarriers for the delivery of antimicrobial agents to fight resistance 
mechanisms.” My role was to develop and apply methods to characterize the 
compounds produced by the consortium, targeting antimicrobial resistance.  
The field of antibiotic resistance mechanisms is a huge research field in itself; 
and although pertinent, is not addressed in this research. The reader is referred to 
literature sources for background of antibiotic resistance evolution and 
mechanisms [59-61].  
This thesis focuses on visualization and drug delivery studies to biofilms – a 
bacterial mode of growth in which bacteria adhere to a surface and form a colony, 
rather than existing as planktonic (individual) cells (figure 9) [62]. 
Bacterial biofilm cultures exist in an aggregate format on the surface of wounds, 
catheters, medical implants, and throughout nature. Covered in a protective 
exopolysaccharide matrix, biofilms can survive through particularly harsh 
environmental conditions. Fluid channels and heterogeneity within the biofilm 
allow for flow of nutrients and protection of low-lying dormant “persister” cells 
to survive attack from antibiotic treatment [63-65].  
Drug delivery to biofilms is a unique pharmaceutical challenge owing to the 
complex structural and physiological characteristics of a biofilm. The 
extracellular polymeric substances (EPS) produced by biofilms consists of 
compounds that can sequester external compounds, such as applied drugs [66, 
67]. Deactivation of antibiotics in a biofilm can cause retarded penetration, as 
well as charged agents in the EPS and matrix, preventing the drug from reaching 
all bacteria, and this can differ between antibiotics and bacteria [68-70].  
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Many clinically problematic biofilms are a result of growth on tissue and 
implanted medical devices (IMDs) caused by Staphylococcus epidermidis [71]. 
S. epidermidis can cause severe complications [72-74] and is often found as 
mature biofilms in skin wounds, ulcers, and burns as the bacterium itself is found 
naturally on human skin [75, 76]. S. epidermidis was the primary strain of bacteria 
explored in this research. 
Visualization of biofilms presents a unique challenge; the heterogenous and 3D 
structure of biofilms represents layers of bacteria with varying metabolic activity, 
and thus varying interactions with drug compounds. Traditional microscopy does 
not provide the resolution, optical sectioning, or spectral detection needed to 
separate interactions within different depth of a biofilm (which can grow more 
than 100 µm in depth in the in vitro model used in this research). It is this 
complication in drug delivery studies to biofilms that is addressed through this 
work; novel methods for both analyzing drug delivery and potential experimental 
treatment are presented to address this gap in the field of biofilm research. 
Figure 9.  Biofilms form through adherence of bacteria and are a common cause of chronic 
infections. Bacteria first adhere to a surface via initial colonization through physical forces 
or appendages. Cell signaling mechanisms are used to stimulate production of the 
extracellular matrix. Mature biofilms consist of water and waste channels found throughout 
a heterogeneous and highly complicated structure in which bacteria can detach and return 
to planktonic form of growth. Image reprinted with permission from Centre for Biofilm 
Engineering.  
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2.2.2 Photopharmaceutics  
 
2.2.2.1 Photodynamic action 
 
Photodynamic action refers to the induction of a light reaction with a compound, 
in which oxygen is consumed, causing a therapeutic effect in biological systems 
[77]. Essentially, upon application of light to a specific compound, photochemical 
processes occur in the compound which cause it to release reactive oxygen 
species (ROS), which are harmful to cells. This process is used in the treatment 
photodynamic therapy (PDT), a method of treatment in which a photosensitizer 
(PS) compound is applied to an effected area and a specific wavelength of light 
is used to selectively activate the compound to release ROS [7, 78, 79].  
The general mechanism of photodynamic processes is shown in figure 10. Like 
the photoexcitation process described in 2.1.1, a photon of light is absorbed by 
the PS, exciting the compound to S1 and T1 via intersystem crossing. From T1; 
the PS can react in two primary patterns; type I or type II PDT reactions. In type 
I reactions the excited PS interacts directly with the substrate to form radicals via 
transfer of a hydrogen atom to the triplet state PS. The radicals produced can 
immediately react with oxygen to form reactive oxygen intermediates toxic to 
biological species [80]. Alternatively, in a type II process T1 interacts directly 
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with molecular oxygen to produce singlet oxygen1 [81], which can go on to can 
damage or kill cells [79, 80] 
In papers VI and VII, PDT protocol was adapted to test as a method for targeting 
bacterial cells within S. epidermidis biofilms. PDT for killing bacteria, termed 
photodynamic inactivation (PDI), has been shown to target multi-antibiotic 
resistant strains while avoiding development of resistance to the therapy [82].  
A natural compound, curcumin, is used as the PS in these studies and is further 
described in the following section (2.2.2.2). Studies of curcumin have 
demonstrated useful anticancer, anti-inflammatory, and antibacterial effects with 
minimal toxicity using a biologically effective dose [83-85].  PDI with curcumin 
has been performed [86-91], but generally uses blue or white light, thus causing 
unnecessary tissue damage with limited light penetration. 
                                           
1 To describe this process in more detail requires a deviation from the aim of this thesis work, but the reader is 
referred to reference 81 for background on the mechanistic details of PDT reactions. 
Figure 10. Schematic Jablonski diagram demonstrating the photodynamic therapy (PDT) 
processes. A photosensitizer (PS) absorbs a photon to be excited from the lower-energy 
ground state to the higher-energy singlet excited state. PS can lose energy by emitting a 
photon from the singlet excited state through fluorescence emission, or through non-radiative 
decay back to the ground state. Alternatively, as in a PDT process, the singlet state can be 
converted to a long-lived triplet excited state through intersystem crossing. The excited triplet 
state can interact with molecular oxygen to produce singlet oxygen (type II reaction) or can 
react with molecular oxygen by electron transfer to form superoxide radicals (type I reaction), 
which can go on to generate hydrogen peroxide and hydroxyl radicals. 
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Curcumin-mediated PDI with 2PE allows for deeper tissue penetration and 
minimal tissue damage due to use of NIR light [92].  
To date, PDI has been explored against planktonic and biofilm bacteria [10, 11, 
89, 93], but has not been demonstrated with 2PE, nor has the distribution and 
interaction of PS in 3D biofilms (and subcellularly in single cell bacteria) been 
visualized. Papers VI and VII address these issues and aim to lay groundwork for 
further translational applications of non-invasive PDI using curcumin. 
 
2.2.2.2 Photosensitizers 
 
Photosensitizers (PS) used in PDT are non-toxic dyes that can undergo a type I 
or type II photodynamic process to produce toxic species targeting cells. The 
interaction of PS with cells in tissue is a key factor in effective PDT; 
understanding this biological interaction is critical when creating new PS or 
assessing a known PS for a new treatment [94, 95]. 
The first PS approved for clinical use, Photofrin, induces skin toxicity to the 
patient, lacks selectivity, and is excited by a lower wavelength (630 nm) thus less 
accessible in thick tissues. A wealth of new PS have been, and are continuously, 
being developed to address these major factors in successful PDT [96], but are 
often difficult to synthesize and have potentially high toxicity to humans. Natural 
compounds with minimal toxicity, excitable by NIR light, and producing fewer 
systemic side-effects are important to characterize for better PDT/PDI.  
In this work, the natural compound curcumin was explored for use of PDI in a 
bacterial system (papers VI and VII). Curcumin is a natural dye, originating from 
the spice turmeric, with a broad absorption spectrum ranging from 300 – 550 nm 
with an excitation maximum at approximately 430 nm [97]. Curcumin has long 
been known for its interactive properties with biological material; and although 
active naturally at certain concentrations, toxicity of curcumin is enhanced by 
activation with light – thus leading to the use of curcumin as a PS in PDT/PDI 
studies [98, 99].  
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The exact photosensitization method by which curcumin acts has not been studied 
extensively but literature data has shown that curcumin takes multiple 
photochemical pathways; including production of singlet oxygen via interaction 
with molecular oxygen, as well as reduction of molecular oxygen to hydrogen 
peroxide and other radicals (figure 11) [99].  
 
The environment of curcumin, such as solvent effects, pH, and extra- or intra-
cellular localization will affect its phototoxic activity. Curcumin is largely 
insoluble in aqueous solutions and is demonstrated to have poor bioavailability. 
Despite this, curcumin has shown success in in vitro, in vivo, and preclinical trials 
[86, 100-102]. Curcumin has a strong two-photon cross section absorption [103] 
and thus could be a promising 2PE PDI agent.  
Subcellular localization of curcumin, as well as 2PE PDI using curcumin as a 
photosensitizer, were addressed in papers VI and VII. Furthermore, challenges in 
solubility and bioavailability of curcumin were addressed by employing 
complexation with a solubility enhancing compound (described in section 4.3.1).  
 
2.2.2.4 Photoactivatable Compounds  
 
Photoactivation can also be used to trigger release of toxic species without the 
need for molecular oxygen (as is needed in type II PDT), or to study cellular 
Figure 11. Upon light irradiation curcumin takes multiple photochemical pathways ending 
in production of singlet oxygen, as well as reduction of molecular oxygen to radicals. 
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processes. A photoactivatable compound is targeted to cells and a light source 
triggers a light-sensitive group of the compound (figure 12). In this work, 
photoactivation was used to trigger the release of nitric oxide (NO) (papers I and 
II). In addition, the compounds used herein were dual-function; release of NO 
was simultaneous to activation (paper I) or modification (paper II) of 
fluorescence, thus enabling tracking of the compound and NO release. 
NO shows experimental promise as an anti-cancer, anti-bacterial, and antioxidant 
agent [104-108]. Ability of exogenous targeted NO to inhibit various 
physiological processes in cell growth and damage cancer cells, as well as de-
aminate nucleoside bases and induce strand breakage in DNA, can be used to 
inhibit cancer cell growth [108]. Although high levels of NO present in tumor 
tissue has been shown to hinder tumor progression [109], both endogenous and 
induced NO are implicated in tumor progression [108, 110, 111], owing to its 
reputation as a “double-edged sword.”   
Given the nature of NO to both repress and promote cancer growth or to both kill 
and aid in microbial infection, spatiotemporal control of NO release in targeted 
delivery is important. As the precise molecular action of NO is still unclear in 
Figure 12. Nitric oxide (NO) photodonors release NO upon light irradiation. Ideally, the 
compound will have entered the cell prior to photoactivation and can release NO 
intracellularly. 
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biological environments, there is a need for non-invasive methods to probe 
release and function.  
Light-triggered NO release for targeted delivery presents an option for specific 
delivery of high concentrations to a biological site using standard PDT techniques 
with potential for spatial and dosage controlled release through non-invasive 
methods, without affecting pH, temperature, and ionic strength [112-115]. 
Furthermore, released NO upon photoactivation can produce cytotoxic results 
without the need for oxygen (as singlet oxygen production does in traditional 
PDT), opening the door to treatment of hypoxic conditions such as deep-seated 
tumors and resistant bacterial communities. 
Non-invasive methods for studying NO release and targeting NO to produce 
cytotoxic effects in a biological system were developed and applied in papers I 
and II, opening possibility for future research in the field of NO targeting. 
 
2.2.3 Drug Delivery 
 
Advances in pharmaceutical science has led to successful treatment of many of 
the most common and harmful diseases and infections. Despite this, promising 
therapeutic compounds face difficult hurdles in targeting disease agents; many 
are inaccessible to the free-form of the drug compound [8]. Furthermore, 
physiochemical properties of the compounds can cause severe side effects at the 
concentration levels required for treatment, thus rendering the compound 
irrelevant in clinical settings [116]. In this research, various methods for 
improved drug delivery were explored. This section describes the fundamentals 
of the three major methods for drug delivery used in papers I-VII. 
 
2.2.3.1 Topical drug delivery 
 
Topical drug delivery overcomes limitations in oral delivery such as degradation, 
systemic side effects, and limited transport. The goal is to deliver active material 
by penetrating the outermost layer of the skin. The complex physical structure of 
skin makes penetration of xenobiotic compounds difficult; the primary function 
of the skin is acting as a barrier to the surrounding environment through complex 
physical and biochemical structure and function.  
Skin is comprised of three layers: the epidermis (outermost layer of skin that 
provides the waterproof barrier), the dermis (containing connective tissue, sweat 
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glands, and follicles), and the subcutaneous tissue made up of fat and connective 
tissue (figure 13) [117, 118].  
 
The outermost layer of the skin, the stratum corneum, approximately 20 µm thick, 
is the first penetration barrier encountered by drugs delivered dermally. Drug 
transport through the stratum corneum involves diffusion of the drug via the 
intercellular pathway, through the lipid matrix, but this pathway is not an easy 
feat for diffusing molecules due to solubility requirements and structural barriers 
[119]. 
Measurements of compound permeation and drug release through tissue is a 
fundamental step in pharmaceutical research. A standard ex vivo assessment is 
human skin models combined with percutaneous absorption studies [120, 121]. 
Excised human skin is obtained from plastic surgery or cadavers and is thought 
to maintain the stratum corneum barrier function for up to 6 months of storage 
[122].  
In this research, penetration and localization of nanoparticle drug carriers through 
ex vivo human and murine skin tissue is explored by employing 2PM, spectral 
detection, and fluorescence techniques such as FRET (explained in 2.1.6). 2PE 
enables illumination with near infrared light, the ideal wavelength for limited 
absorption in skin, thus location of the diffused particles can be visualized. 
Figure 13. Histological skin structure demonstrating the three primary layers of 
mammalian skin. The stratum corneum, the outermost layer, is the first barrier to drug 
diffusion. This research focuses on imaging of drug delivery through the stratum corneum. 
Image used with permission from [119]. 
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Through this technique, 3D images of 100 µm in depth and more can be collected 
to demonstrate location of an exogenous compound within skin after application. 
 
2.2.3.2 Cyclodextrins for drug delivery 
 
Common challenges in pharmaceutical design are aqueous solubility [123], 
penetration in various biological environments [124], delivery of active agents to 
targeted cells [125], and degradation. An approach for improved delivery of 
pharmaceutical compounds – delivery that could improve solubility in 
biologically-relevant solution, enhance penetration through tissue/cells/etc, and 
block degradation – is complexation with another compound. Cyclodextrins are 
used extensively for this purpose due to their favorable physiochemical properties 
and utility as “carriers” [126, 127]. The use of CDs has been a key strategy within 
the CyclonHIT ITN project, thus appears in this research as a common theme.  
Cyclodextrins (CDs) are chemically and physically stable cyclic oligomers of 
glucose, soluble in water, consisting of a hydrophobic core cavity and hydrophilic 
outer surface. CDs can form inclusion complexes with guest molecules, through 
complexation of a drug compound within the CD cavity, and can thus alter 
biological interaction of a guest drug molecule with its environment. The most 
commonly used CDs are α, γ, and β, differing in the glucopyranose units making 
up the CD structure, thus also differing in cavity size [128-130]. Among these, 
CD derivatives are often developed with altered physiochemical or 
biopharmaceutical properties to enhance complexation or utility. An example of 
this is charge functionalization of β-CDs for enhanced penetration and drug 
delivery in bacterial biofilms as was explored in paper IV.  
As shown in figure 14, the association of free CD and drug form a drug-CD 
complex. The complex is maintained by a dynamic equilibrium between free drug 
and free CD molecules given the size of drug and size of the CD inner cavity are 
sufficient to form a favorable complex, while physiochemical properties of the 
complex are studied to determine strength of the complex itself within solution 
and further biological studies.  
In papers V and VII, potential of CDs to increase treatment efficacy, via CD-
complexation with known antibacterials, was studied. 
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Figure 14. (A) Structure of cyclodextrins (CD); n = 1, 2, or 3 if referring to α, β, or γ – CD, 
respectively. Image modified with permission from [130]. In papers IV – VII β- and γ-CDs 
were used. (B) Drug-CD inclusion complex shown as a 1:1 drug-CD complex. The 
hydrophilic exterior of the CD enables water solubility while the hydrophobic inner cavity 
allows for inclusion of hydrophobic ‘guest’ molecules.  
n 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3. Scientific Objectives 
3. Scientific Objectives 
28 
 
3 Scientific Objectives 
 
The overall aim of this thesis was to develop biophotonics approaches for 
studying delivery of photopharmaceutics and antimicrobials to biological 
systems. The specific aims of each paper are described belo
 
Paper I This paper aimed to demonstrate if two photon excited 
photorelease could be implemented in a cellular system. What 
causes cell toxicity in two photon excited photodynamic therapy 
with a nitric oxide photodonor? 
 
Paper II 
 
This paper aimed to track delivery of nitric oxide (NO), in a 
biological sample. Can förster resonance energy transfer be used to 
non-invasively monitor NO release with high specificity? 
 
Paper III 
 
The aim of my contribution was to measure and analyse the spectral 
characteristics of silica nanoparticles. Furthermore, to determine 
where the particles localize in human skin. 
 
Paper IV The aim of this paper was to understand how cyclodextrin based 
nanoparticles penetrate biofilms and how the charge of a 
cyclodextrin might change penetration – does neutral, negative, or 
positive charge produce better penetration? 
 
Paper V 
 
The goal of this paper was to determine if complexation with 
cyclodextrins can make antibiotics more effective for treating 
bacterial infections. 
 
Paper VI 
 
How can two photon excited photodynamic inactivation be 
implemented in a bacterial biofilm? 
 
Paper VII 
 
Where do photosensitizers localize in biofilms and does 
complexation with cyclodextrin improve efficacy of photodynamic 
inactivation with curcumin? A non-invasive diagnostic method for 
measuring treatment efficacy using two photon microscopy was 
presented.  
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4 Methods 
 
4.1 Microscopy and spectroscopy 
 
4.1.1 Multiphoton microscopy 
 
The MPM experiments in paper II – VII were performed using an LSM 710 NLO 
microscope (Carl Zeiss, Jena, Germany) equipped with a mode-locked 
femtosecond pulsed Mai Tai DeepSee laser tunable in the wavelength region 700-
1100 nm and Plan-Apochromat 20x water-immersion objective (NA 1.0) (figure 
15, left). Emission was registered with descanned (internal) detectors using fully 
opened pinhole, and recorded in varying channels corresponding to the 
fluorophores under investigation (varies throughout papers I – VII). The 
experiments in paper I were performed on an inverted custom built MPM (figure 
15, right). 
Emission spectra was acquired using the spectral detector in the emission range 
of 416 to 727 nm at a resolution of 10 nm. This was also performed simultaneous 
to imaging (“spectral imaging”), which enables separation between fluorescence 
signals that could otherwise present as bleed-through or signal overlap in imaging 
alone. 
2PE photorelease was performed, in papers I, VI, and VII, by sequential scanning 
of a selected region with the laser throughout a pre-determined number of 
iterations (figure 16).  
Figure 15. Two different multiphoton microscopy (MPM) setups were used in this research; 
a commercial system by Carl Zeiss shown on the left and the custom-built experimental 
setup shown on the right. 
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Images were recorded prior to scanning, and in between each set of scanning 
iterations. The number of iterations were chosen to deliver a specific light dosage, 
calculated by using pixel dwell time (in µs), image size (i.e. scanning region size, 
in pixels), and estimated laser intensity after transmission through the objective 
lens (in mW). The sequence of images and resultant spectra were used to evaluate 
photorelease of both an NO-releasing system (paper I) and a photosensitizer 
system (curcumin, papers VI and VII). 
Analysis of images and spectra from TPM was performed using ZEN (Carl Ziess, 
Jena, Germany), ImageJ (U.S. National Institutes of Health, Bethesda, 
Maryland), and Matlab (The MathWorks, Inc., Natick, Massachusetts, United 
States) software. 
4.1.2 Structured illumination and Airyscan microscopy 
 
Two different super resolution methods were explored for imaging of bacterial 
biofilms in this research. Super resolution of S. epidermidis biofilms was first 
performed using an ELYRA S.1 structured illumination microscope (Carl Zeiss, 
Jena, Germany). In paper VII, a Plan-Apochromat 63x/1.4 Oil immersion 
objective was used with live S. epidermidis biofilms grown in optical quality glass 
petri dishes. Biofilms were stained with FM 4-64 dye to image the membrane and 
Figure 16. General principle behind two photon (2PE) photodynamic inactivation of 
biofilms. Laser scanning is performed with 2PE in a chosen region of interest within the 
sample to excite a photosensitizer. 
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co-stained with the test compounds for the study. Two excitation lasers were 
used: 405 nm and 561 nm to excite curcumin and FM 4-64, respectively. Band 
pass filters, 570-650 nm and long-pass 750 nm were used to detect fluorescence 
signal in channels corresponding to curcumin and FM 4-64. Images were 
processed using the inherent structured illumination reconstruction in ZEN 
software accompanying the ELYRA microscope. Images were analysed using 
ZEN and ImageJ. This technique was found to be inefficient for live biofilms due 
to movement of the sample. 
Following imaging with a SIM microscope, Airyscan confocal imaging was 
performed using an LSM 880 (Carl Zeiss, Jena, Germany), equipped with a 32 
channel GaAsP spectral detector and Plan-Apochromat 63x/1.4 water objective. 
Laser excitation was split into two channels; 561 nm for excitation of the bacterial 
membrane stain FM4-64 used in both papers, 405 nm for curcumin excitation 
(paper VII), and 488 nm for FITC excitation (paper V). Detection was performed 
using a combination of band-pass filters; 570-620 nm with a 570 nm long-pass 
filter and 495-550 nm band-pass to collect fluorescence emission of FM4-64 and 
curcumin/FITC, respectively.  
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4.1 Pharmaceutical targets 
 
4.1.1 Biofilm model 
 
Biofilm samples were prepared using a biofilm model for S. epidermidis (strain 
ATCC 35984 / RP62A) bacteria cultured as described below, and subjected to 
various imaging and analysis experiments (figure 17). 
Figure 17. Experimental setup for biofilm studies. Biofilms are formed in optical quality 
culture dishes for 48-72 hours and studied live directly on the microscope stage. Biofilm 
viability can be studied using viability staining in real-time. Photoinactivation is performed 
using laser scanning through chosen regions of interest. Drug delivery is monitored using 
two photon microscopy and spectral imaging; images are collected in z-stacks to form 3D 
images. 
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Cultures were obtained from maintained subcultures in tryptic soy agar plates and 
grown overnight in aerobic atmosphere at 37 ͦ C. Second day overnight cultures 
were diluted in tryptic soy broth (TSB) to optical density O.D. ~ 0.2-.3; 
corresponding to ~108 colony-forming units per ml. Biofilm formation occurred 
in either pre-sterilized polycarbonate optical quality glass-bottom 3.5 cm 
diameter cell culture dishes (No. 1.5 glass thickness, Ibidi, LRI Instrument AB, 
Lund, Sweden) or pre-sterilized polycarbonate 96-well multi-well plates. 
Aliquots of 2 mL or 200 µL of bacterial/TSB inoculum containing approximately 
108 cells/mL were transferred into each 3cm petri dish or 96-well plate, 
respectively. Biofilms were incubated under aerobic atmosphere at 37 ͦ C for an 
initial incubation period of 24 h to ensure attachment. After the first 24 h, liquid 
medium was carefully aspirated and replaced with fresh sterile TSB to remove 
planktonic cells. TSB was replaced every 24 h for the remainder of the incubation 
time of each sample.  
Immediately prior to imaging or treatment with compound; biofilms were washed 
carefully with PBS (pH 7.4) to remove planktonic cells. During imaging, biofilms 
were kept in 3 mL PBS and imaged directly on the microscope stage using either 
a water-dip objective in an upright microscope setting (figure 17) or water/oil-
immersion objective in an inverted microscope setting. 
 
4.2.2 Eukaryotic cell culture 
 
Human squamous cancer cell line A431 was cultured in a sterile cell culture 
facility. The general protocol for all cellular experiments described in this work 
is as follows:  
A431 cells (HPA cultures, Salisbury, UK) were cultured at 2x105 cells per mL in 
full-growth minimum essential media (MEM) supplemented with 10% fetal 
bovine serum (FBS), 5% glutamine, and 5% non-essential amino acids (NEAA) 
at 37 degrees Celsius at 5% CO2. MEM, phosphate buffered saline (PBS, pH 7.4), 
glutamine, NEAA, and FBS (EU approved South American origin) were obtained 
from Thermo Fischer Scientific, Gothenburg, Sweden. For multi-well 
experiments, cells were seeded in 96-well plates at 10,000 cells per well and 
maintained at 37 ͦ C and 5% CO2 prior to experimentation. Cells used for imaging 
were seeded in tissue culture treated glass bottom petri dishes suitable for optics 
at 60 000 cells per mL (Ø= 3 cm, Ibidi, LRI Instruments, Lund, Sweden). Cell 
fixation was performed using 4% formaldehyde solution prepared in PBS (pH 
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7.4). Cells were washed carefully with PBS and the formaldehyde solution was 
added to the culture for 20 minutes at room temperature. Cells were then washed 
carefully twice with PBS and 2mL PBS was added to the imaging dishes for both 
inverted and upright microscopies. 
4.2.3 Cell-based assays 
 
Herein, two different cell viability assays were used for assessment.  The basis of 
these assays is similar; cells are incubated with a reagent that is converted to a 
colored or fluorescence product by viable cells. Cells that die are not able to 
produce this signal, thus fluorescence readouts are proportional to the number of 
viable cells present in the culture (figure 18).  
The MTT tetrazolium assay uses the compound MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide), which is converted into formazan, a purple 
product with absorbance maximum of 550-570 nm, by cells with an active 
metabolism. Thus, viable cells are measured by measuring absorbance of the cell 
culture following treatment with MTT.  
The general protocol for the MTT assay used in this work is as follows: MTT 
substrate is diluted in aqueous cell media and added to the cell culture. After 4 
hours of incubation, MTT solution is replaced with hydrochloric acid diluted in 
DMSO. Hydrochloric acid adjusts the pH of the solubilized formazan to provide 
maximum absorbance. Absorbance is then measured at the peak emission of 
formazan using a SpectraMax M2 Multi-mode microplate reader (Molecular 
Devices, Berkshire, UK). Generally, experiments are performed in replicates and 
statistical analysis is done using the excel data analysis toolbox.  
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The resazurin reduction assay is an alternative to the MTT assay. Resazurin is a 
cell permeable redox indicator that monitors viable cell counts. Resazurin is 
soluble in physiological buffers and can be added directly to cell culture once 
solubilized. Cells with an active metabolism (i.e. viable cells) can reduce 
resazurin into resorufin, a fluorescent product, which can be monitored via 
fluorescence spectroscopy measurements.  
The general protocol for the resazurin reduction assay is as follows: AlamarBlue 
reagent (Thermo Fisher Scientific, Stockholm, Sweden), is added to cell culture 
at 10% of the cell culture media volume. The cells are incubated for 4 hours with 
solution and either absorbance (560-570 nm) or fluorescence (590 – 600 nm) of 
the cells with solution is read using a SpectraMax M2 Multi-mode microplate 
reader. Viable cell counts are determined by analyzing absorbance vs. compound 
concentration as described by the manufacturer protocol.  
Figure 18. Application of the MTT assay. Healthy cells are cultured in 96 well plates and 
the drug compound is added. Light photoactivates the compound to release toxic species. 
Toxicity is measured with reduction of tetrazolium dye to formazan (purple), reduced by 
viable cells. 
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4.2.4 Skin permeation studies  
 
In this research, open chamber jacketed Franz diffusion cells (PermeGear, Inc., 
Pennsylvania, USA) were used, shown schematically in figure 19A. The donor 
chambers hold test compound and the receptor chamber contains a collection 
medium (in this research, phosphate buffered saline was used for all 
experiments). The outer compartment is filled with water which is circulated at 
30 ͦ C constantly throughout the experiment. 
Cadaver skin for all experiments was obtained from Caucasian females as leftover 
specimens from breast reduction surgeries, through an agreement with 
Sahlgrenska University Hospital (Gothenburg, Sweden). Samples were 
Figure 19. (A) Standard flow-through Franz diffusion cell used for skin permeation 
studies with ex vivo skin samples. Test compounds are added to the donor chamber in 
contact with the skin sample and PBS is added to the acceptor chamber. (B) Following 
incubation skin samples are removed and analyzed for biodistribution of the test 
compound using two photon microscopy and spectral analysis. 
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maintained at a temperature of -70 ͦ C for no longer than 6 months. Prior to 
experimentation, samples were thawed at room temperature, subcutaneous fat 
was removed using a scalpel, and samples were mounted on the chamber with the 
stratum corneum facing the donor chamber. Samples were kept under heat 
circulation for 4 – 24 hours depending on the experiment.  
Following exposure samples were carefully washed with PBS and the exposed 
region was separated using an 8 mm biopsy punch and then mounted to a custom-
made imaging chamber prepared by attaching a No. 1.5 glass cover slip (.17 mm 
thickness, 24 mm diameter, Bioscience Tools) to a microscopy slide via double-
sided tape (figure 19B).  
 
4.2 Drug delivery 
 
4.3.1 Nitric oxide photodonors 
 
Two novel compounds designed for photodynamic release of nitric oxide (NO) 
were developed by collaborators within the Marie Curie ITN project No. 608407, 
with the group of Salvatore Sortino at University of Catania (Catania, Italy). The 
compounds were then tested in biological systems as part of this thesis work. 
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In paper I, a dual-function NO photodonor was adapted with a fluorescent 
reporter, and designed to be excited by both 1PE and 2PE, such that upon release 
of NO, the fluorescence of the PS is activated and an increase in fluorescence 
intensity can be measured and directly correlated to release of NO.  The 
previously published compound [131] (CPA, figure 20) consists of a cupferron 
(CP) O-alkylated with anthracene, a common fluorophore exhibiting blue (400-
500nm peak) fluorescence. Prior to irradiation, the fluorescence of CPA is 
quenched due to charge transfer within the molecule, while upon irradiation, the 
anthrylmethyl carbocation and CP is released, activating a fluorescent co-product, 
while resultant CP spontaneously releases NO when decomposed (figure 20).  
Figure 20. Cupferron-anthracene compound (CPA) employed as a nitric oxide photodonor 
in paper I. Cupferron O-alkylated with anthracene (1), upon light activation, forms two 
separate species; anthrylmethyl carbocation and CP. Fluorescence of 1 is quenched due to 
charge transfer of the intact compound, upon photoactivation, a fluorescent co-product (2) 
is formed and CP spontaneously decomposes to release nitric oxide (NO). Figure reprinted 
with permission from [13]. 
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An alternative method for targeted NO release was demonstrated in paper II. A 
nanoparticle (NP) system designed to release NO with inherent fluorescence 
tracking via FRET was developed. The NPs were made of di-block poly-ε-
caprolactone and polyethylene glycol copolymers covalently linked to rhodamine 
B. The polymeric NPs contained rhodamine in the core while a green fluorescent 
NO photodonor (“NBF”) was trapped within (figure 21). NBF and rhodamine 
acted as a FRET pair, wherein excitation of NBF led to excitation and emission 
of rhodamine through a FRET process, with simultaneous release of NO upon 
excitation of NBF. 
Figure 21. Di-block PEG-PCL nanoparticles used in paper II. Copolymers form a PEG 
core-shell structure with a hydrophobic PCL core, ideal for housing a lipophilic drug. The 
hydrophilic PEG shell provides solubility and stability of the NP structure, while 
rhodamine is covalently integrated as a fluorescent label in the di-block copolymer 
(“mPEG-PCL-Rhod”). An NO photodonor, consisting of an NO photoreleasing unit and 
green fluorescent unit, is loaded in the nanoparticle core. Figure adapted with permission 
from [12]. 
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4.3.2 Cyclodextrins 
 
Cyclodextrins for drug delivery (section 2.2.3.1) was demonstrated in a microbial 
biofilm in papers IV-VII. CDs shown in this work were developed by 
collaborators CycloLab (Budapest, Hungary) in papers IV, VI, and VII and the 
group of Konstantina Yannakopoulou at the National Center for Scientific 
Research Demokritos (Athens, Greece) in paper V. In paper IV, three β-
cyclodextrins were labelled with rhodamine and functionalized with positive, 
negative, or no additional moieties. Rhodamine labelled βCD polymers 
(RBβCDp) were prepared via functionalization of previously prepared CD 
Figure 22. β-cyclodextrins functionalized with rhodamine and charged-moieties. Reprinted 
with permission from [15]. 
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scaffolds conjugated with rhodamine B [132, 133] as shown schematically in 
figure 22, described in more detail in [15]. 
Following paper IV, in which ideal charge functionalization of cyclodextrins for 
penetration into microbial biofilms was found, CDs were then loaded with 
antibiotics to determine if a CD-antibiotic complex would be more successful in 
targeting biofilm-encased bacteria than the antibiotic alone. 
In paper V, previously synthesized γ-cyclodextrins were modified with positive 
charge and labelled with fluorescein (FITC) for fluorescence tracking [134]. 
Stock solutions of γ-CDs were prepared in sterile 1x PBS (pH 7.4) at a 
concentration of 100 µM. γCD-antibiotic complex was prepared by dissolving 
CD in sterile PBS and stirring to achieve dissolution at room temperature and 
adding antibiotic sodium salt (rifampicin or oxacillin) under stirring in a ratio of 
1:1.5 (CD:antibiotic).  
Lastly, in papers VI and VII, CDs were used to enhance aqueous solubility and 
biological penetration of curcumin (section 2.2.2.2). A curcumin-CD complex 
was created by combination of hydroxypropyl-γ-cyclodextrin (HPγCD) provided 
by CycloLab and curcumin (Sigma-Aldrich, Stockholm, Sweden). HPγCD was 
dissolved to a concentration of 112 g/L in 0.18 mol/L sodium hydroxide solution. 
Curcumin was added to a concentration of 15 g/L. The solution was agitated and 
after complete dissolution of curcumin, the pH wad adjusted to 6.0. Solutions 
were diluted from stock solution to 10 and 40 µM in PBS adjusted to pH 6.1 with 
HCl.  
4.3.3 Nanoparticles for drug delivery 
 
In paper III, localization of nanoporous silica particles (SPs) (sizes 440 nm, 2 µm, 
and 7 µm) in tissue was measured using MPM and spectral detection. 
Luminescent SPs were developed by collaboration with Nanologica (Stockholm, 
Sweden). SPs were functionalized with carboamino groups leading to 
luminescent nanosized carbon dots forming within the porous SPs. 
A full spectral characterization of the particles was performed. SPs were applied 
to skin using franz cell diffusion (section 4.2.4) and imaged using MPM (4.1.1). 
SPs were sonicated prior to analysis in PBS (pH 7.4), at a concentration of 2 
mg/mL. Following skin permeation studies, the mounted skin samples were 
imaged using emission channels corresponding to the SPs (434 – 552 nm) and 
autofluorescence of skin (552 – 640 nm). Ideal 2PE excitation was acquired prior 
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to imaging using spectral detection. 3D images were rendered using 1 µm z-stacks 
and analyzed using ZEN software and ImageJ.  
 
 
Figure 23. Study of nanoparticle localization in skin using franz cell diffusion and 
multiphoton microscopy. 
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5 Results 
 
5.1 Paper I 
 
In this project, the inherent confinement of two photon excitation (2PE) was used 
as a tool to demonstrate cytotoxicity, or lack thereof, of an NO-releasing PS 
(CPA, described in 4.3.1) 
Upon irradiation with 745 nm 2PE, fluorescence emission of CPA is activated 
and increases with increasing light dosage as shown in figure 24. Previous 
spectral studies of CPA in solution confirmed release of NO at the start of light 
irradiation, simultaneous to increase in fluorescence intensity in 1PE [131]. 
Combined with the 1PE and 2PE imaging in figure 24, this indicates that NO is 
being produced simultaneously within the cell culture. 
Figure 24. Two photon microscopy (TPM) and confocal images of A431 cells incubated 
with CPA in FBS-media for 4 hours. (A) TPM image  (λexc = 745 nm), cells incubated 
with 5% CPA. (B) Confocal image (λexc = 405 nm), cells incubated with 20% CPA and 
fixed with 4% formaldehyde (in PBS). (C) Cells incubated with 5% CPA and subjected to 
increasing 2PE photoactivation with light doses of 0.9, 1.7, 2.6, and 4.4 J using laser power 
of 19 mW at the sample. Images reprinted with permission from [13]. 
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The cytotoxicity of CPA against cancer cells with 1PE irradiation was first 
studied. Then, CPA was excited with 2PE light to determine if the same 
cytotoxicity could be produced using 2PE PDT. During this experiment, the same 
cytotoxicity to cells could not be reproduced using 2PE, as can be seen in figure 
25B.  
Figure 25. Cell toxicity following photoactivation of CPA in A431 cells with one-photon 
(1PE) or two-photon (2PE) excitation. Cells were treated with 0, 1.25, and 2.5 % CPA and 
irradiated with one-photon blue light at a dosage of 0 or 5 J/cm2. A) Cell toxicity with 1PE 
photoactivation. (B) Cell toxicity with 2PE photoactivation. (C-D) Schematic illustration 
of 1PE UV light irradiation vs. confined 2PE irradiation. (E) Toxicity following treatment 
with scavengers of peroxynitrite (uric acid), superoxide (superoxide dismutase), and 
hydrogen peroxide (catalase), at concentrations of 100 ug/mL in PBS. Cells were treated 
with 2.5% CPA or cell media only, and irradiated with 0 or 5 J/cm2 UV light. Statistical 
analysis performed from replicates of n=6. Error bars represent standard error of mean of 
replicates. Figure reprinted with permission from [13]. 
 
5. Results 
45 
 
In the 2PE case, superoxide is not present in the same levels as 1PE; UV-
irradiation produces superoxide whereas 2PE NIR does not to the same degree 
[135]. As it is referenced in literature that the cytotoxic effect of NO may be due 
to the production of peroxynitrite, through reaction of superoxide with NO [136], 
this led to the hypothesis that the lack of superoxide accompanying 2PE 
irradiation is the cause of lack of toxicity, since peroxynitrite might not be 
produced within the cells (figure 25). 
To investigate this potential cause of cytotoxicity, cell toxicity with 2PE 
irradiation was measured in the presence of a peroxynitrite scavenger (with 
superoxide and hydrogen peroxide scavengers as controls).  The results, figure 
25E, show that when peroxynitrite is removed from the cells using a scavenging 
molecule, the viability of the cells is slightly recovered. These results are only a 
first investigation into this hypothesis; further experiments are needed to 
elucidate the mechanism.  
5.2 Paper II 
 
In this research, nanoparticles releasing NO upon irradiation with a specific 
wavelength of light were designed (section 4.3.1). To understand how and where 
NO is delivered in this scenario, the NPs were designed as a Förster resonance 
energy transfer (FRET) pair, such that monitoring FRET signal should be directly 
correlated to the release of NO.  
My role in this paper was to measure spectra of the NPs in solution as well as 
monitor penetration of the NPs in human skin (figure 26). NPs with rhodamine 
core (acceptor), and with or without NBF (donor), were monitored with excitation 
to rhodamine or NBF only. Indication of a FRET process can be seen when 
rhodamine-core NPs loaded with NBF, excited at the ideal 2PE excitation of 
NBF; demonstrate stronger emission in the rhodamine (red) channel, rather than 
NBF (green) channel. While the NPs did penetrate and accumulate in skin, the 
design of the FRET NP system should be addressed prior to use as a FRET 
reporter of NO in tissue. Firstly, the images and spectral quantification confirmed 
that NBF appears to be released at the surface of the skin, accumulating in lines 
at the surface, while the rhodamine-containing core of the NPs successfully 
penetrate (figure 26).  
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Figure 26. (A) Fluorescence emission spectra (λexc = 450 nm) of NPs with (a) NBF only (b) 
rhodamine only (c) rhodamine-NBF. (B) Two photon excitation fluorescence emission spectra 
(λexc = 900 nm) corresponding to A. (C) 2PE images of human skin samples after 24 h incubation 
with (i) Rhodamine-NPs (ii) NPs loaded with NBF (iii) Rhodamine-NPs with NBF and (iv) PBS 
only, (v) overaly 3D image. Images reproduced with permission from [12].  
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In addition, a FRET pair should consist of an acceptor fluorophore which is not 
excited by the same wavelength as a donor fluorophore (section 2.1.6). The NPs 
in this paper use a rhodamine-NBF pair, and while it meets this requirement with 
1PE, both rhodamine and NBF are excited by the 2PE excitation wavelengths 
required. Thus, the fluorescence signal is not an accurate representation of FRET, 
and thus cannot be used as a quantifiable reporter of NO release.  
Although the NP system would need to be re-evaluated for direct correlation 
between FRET signal and NO release, as well as full penetration into tissue, the 
system demonstrates, via proof-of-principle studies, a novel tool for monitoring 
release in optically dense tissue.  
 
5.3 Paper III 
 
In this paper, nanoporous silica particles ranging from 400 nm to 7 µm were 
developed (particles described in 4.3.3) and delivery to skin was measured using 
three different methods. My role in this paper comprised of performing ex vivo 
transcutaneous drug delivery studies and measuring particle location in solution 
and tissue. 
Initial spectral analysis was performed in solution (figure 27). As seen in the 
figure, spectral profiles with both 1PE and 2PE were similar, confirming that the 
luminescent property of the particles are retained with 2PE excitation. 
Additionally, as it has been shown that carbon dots exhibit excitation-dependent 
photoluminescence that is “tunable” in the visible range [137]; the excitation-
dependent luminescence emission seen provides evidence that carbon dots have 
formed within the particles. 
Depth of penetration of the particles was shown using MPM. Resultant images 
from one particle, nSP (400 nm in size), are shown in the figure; nSP appears to 
accumulate a depth of 25 µm, whereas the larger micron size particles were 
visualized only to 14 µm (results shown in paper III).  
To confirm that the fluorescence emission seen is a result of nSP accumulation, 
rather than autofluorescence from skin, spectral imaging was performed. Separate 
regions were selected; region 1 (R1) appears as localized nSP in the skin furrows 
and region 2 (R2) appears to be autofluorescence of the skin. As seen in figure 
27E, peak emission from R1 is 
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that expected from nSP, whereas emission from R2 is a weaker signal more 
characteristic of skin autofluorescence. 
Figure 27. (A) Spectral characterization of nSP in solution (2 mg/mL in PBS) with λexc = 
350 – 450 nm and (B) two photon excitation (2PE) with λexc = 690 – 920 nm. (C) Multiphoton 
microscopy data of porcine skin treated with nSP. Images are shown at varying tissue depth, 
represented in µm from the surface of the skin. nSP emission is shown in green, 
corresponding to 431 – 552 nm detection. Autofluorescence is shown in red, corresponding 
to 552 – 640 nm detection. Images are collected as z-stack images, with 1 z-stack acquired 
every 1 µm. Field of view of images shown corresponds to 424 x 424 x 1 µm. (D) Two 
photon spectral imaging data of porcine skin treated with nSP. Spectra were acquired using 
spectral detection in the range of 416 to 727 nm at a resolution of 10 nm. 1 z-stack, at a depth 
of 25 µm from the skin surface, is shown here. (E) Emission from R1 and R2 in image D, 
R1 corresponds to autofluorescent signal of skin while R2 corresponds to suspected nSP 
location. Field of view of images shown corresponds to 424 x 424 x 1 µm.  
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5.4 Paper IV 
 
In this paper, MPM was used as a method for measuring penetration of an 
experimental drug carrier developed by a collaborating company, CycloLab 
(4.3.2). The research aimed to determine which charge-functionalization of the 
drug-carrier, a β-cyclodextrin (β-CDs) tagged with a fluorescent reporter, more 
efficiently penetrated a biofilm.  
Both monomer and polymer β-CDs were adapted with fluorescence (rhodamine, 
peak emission = approx. 600 nm) and charge-functionalization and 2PE emission 
spectra of the entire range of β-CDs incubated with SYTO9 (peak emission = 
approx. 500 nm) stained S. epidermidis biofilms was performed (figure 28).  
Interestingly, minimal fluorescence signal from the monomer β-CDs was 
collected throughout the biofilm structure. Whereas the polymer β-CDs show a 
strong emission peak with cationic charge (figure 28).  
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This initial experiment concluded that primarily polymer β-CDs would be 
monitored in the biofilms as no signal could be found for monomers. 
Understanding the mechanism behind the difference in both monomer vs polymer 
and charge requires further experimentation that was beyond the scope of this 
publication. 
MPM images of charged and fluorescent polymer β-CDs incubated with SYTO9 
stained S. epidermidis biofilms are shown in figure 29. Biodistribution of the β-
CDs (red emission) in comparison to bacterial cells (green emission) was 
monitored via 3D imaging and confirmed with spectral detection, in which 
spectra from bacteria and β-CDs can be distinguished.  
As can be seen in the figure, the cationic β-CDs are significantly more distributed 
throughout the biofilm compared to the others. This could suggest that CDs 
designed for drug delivery to biofilm cultures may be enhanced by 
functionalization with cationic charge but further analysis of imaging data should 
be performed to confirm the findings.  
 
Figure 28. Two photon emission spectra of rhodamine labelled cyclodextrin (RB-CD) 
monomers and polymers after incubation with S. epidermidis biofilm. Spectral data was 
extracted from spectral imaging of biofilms with excitation of 860 nm. 
Neutral/cationic/anionic charged RB-CDs were measured. Signal from rhodamine emission 
is seen from cationic polymer cyclodextrins, whereas monomer cyclodextrins show 
minimal emission when incubated with the biofilm.  
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Figure 29. Multiphoton microscopy (MPM) data of S. epidermidis biofilms after incubation 
with rhodamine labelled cyclodextrin polymers (RB-CD). Green corresponds to SYTO9 
staining (453-549 nm) and red corresponds to the RB-CD (562-718 nm). Field of view of 
3D volumes corresponds to 424x424xz µm where z represents height from the adhered 
surface of the biofilms. (A) control biofilm, (B) Neutral charged RB-CD, (C) negatively 
charged RB-CD, (D) positively charged RB-CD. (E-H) corresponding 2PE emission 
spectra for A-D, respectively. (I,J) 3D surface rendering corresponding to C and D. A 
thresholding algorithm was implemented to asses ratio of SYTO9 (bacteria) to RB-CD 
signal. Images used with permission from [15]. 
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5.5 Paper V 
 
In paper IV, it was shown that positively charged cyclodextrin (CD) polymers 
most efficiently penetrate and localize within 3D biofilm structure. In this study, 
positively charged cyclodextrins are loaded with antibiotic and measured for 
efficacy against S. epidermidis biofilms. γCD labelled with fluorescein (γCD-
FITC, section 4.3.2) was first monitored for localization to a biofilm, and then 
loaded with oxacillin and rifampicin for further studies of antibiotic efficacy.  
MPM and spectral analysis was used to monitor the localization of the antibiotic 
loaded CDs. Figure 30 shows MPM images of S. epidermidis-BFP (bacteria 
expressing blue fluorescence) incubated with γCD molecules. To evaluate 
colocalization of S. epidermidis with γ-CDs, a colocalization scatter plot of S. 
epidermidis-BFP vs. FITC was created. BFP and γCys appear to be colocalized, 
although this does not indicate if the CD was taken up internally in the bacteria. 
To better understand the subcellular localization γCys, Airyscan microscopy was 
used for higher resolution imaging, shown in figure 31. In the high-resolution 
images, it appears as if γCys is localized in the EPS surrounding the bacteria, 
rather than intracellularly. This could suggest that γCys could act to penetrate the 
biofilm, while the antibiotics are released prior to uptake into the bacteria.  
To determine if the antibiotic activity was in fact increased by delivery with CDs, 
biofilm viability was measured using a microtiter plate assay with serial dilutions 
of CD-antibiotic complex, and complimented with 3D viability imaging to 
understand varying effect throughout the biofilm structure (figure 32). As can be 
seen in the figure, in which biofilms are stained with propidium iodide (PI) for 
membrane-compromised cells, increased PI signal can be seen for biofilms 
treated with γCys, indicating inherent antibacterial activity of the CD alone. 
Ethanol-killed biofilms were monitored for reference. Biofilm viability following 
treatment with γCys-rifampicin and γCys-oxacillin complexes, compared to free 
antibiotics, were measured using the resazurin microtiter plate assay. A 
statistically significant reduction in biofilm viability was found with γCys 
complexed with rifampicin (figure 32B). 
This work demonstrates potential increased effect of antibiotics to a biofilm by 
complexation with CDs, and demonstrates complementary methods for 
monitoring drug delivery and toxicity using imaging, thus providing a better 
understanding of how drugs interact with the complex 3D structure of biofilms. 
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Figure 30. (A) Multiphoton microscopy images of S. epidermidis biofilms incubated with 
γCys-FITC (100 µM in PBS, pH 7.4, 30 min incubation). Fluorescence emission was 
collected in 2 channels corresponding to blue BFP emission of bacteria (λ = 399 – 493 nm) 
and green emission of  FITC (λ = 504 – 659 nm), an overlay image is shown to demonstrate 
overlap of signal. 3D image stacks reconstructed from 80 1 µm image slices. Field of view 
424 x 424 x z µm (B) Spectral profile of γCys-FITC within the biofilm corresponding to 
images in A. 2PE fluorescence emission intensity (A.U.) shown for z levels 0 – 80 µm 
collected at 10 nm increments. (C) Colocalization scatter plot corresponding to aimges in 
A. Colocalization was monitored by plotting fluorescence intensity in the BFP channel.  
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Figure 31. Airyscan confocal images of S. epidermidis biofilms incubated with γCys- FITC 
(100 µM in PBS, pH 7.4, 30 min incubation). 
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Figure 32. (A) MPM data of S. epidermidis biofilms (72 h growth) treated with γCys, media 
(control), γCys-oxacillin, γCys-rifampicin, or ethanol (99.9%). Blue fluorescence represents 
bacterial cells (S. epidermidis-BFP), red fluorescence represents membrane-compromised cells 
(propidium iodide (PI) staining). Images were collected as Z-stacks of 1 µm and shown in the top 
panel as 3D representations of 70 µm stacks, with field of view 424 x 424 x 70 µm. (B) Biofilm 
bacterial viability measured via resazurin microtiter-plate assay; fluorescence intensity is 
represented on the y-axis; decreased fluorescence intensity is equivalent to a decrease in cell 
viability. Activity of oxacillin (oxa) and rifampicin (rif) were tested against biofilms both alone and 
complexed with γCys (1:1.5 ratio of γCys to antibiotic in phosphate buffered saline). 
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5.6 Paper VI  
 
In this paper, photodynamic inactivation (PDI) of biofilms is demonstrated for 
use in studies of bacterial interactions with light, which could lead to using light 
to study more complex biofilm dynamics (figure 33) [138].  
 
2PE combined with photoinactivation using curcumin is optimized to selectively 
target and kill bacteria within a chosen region of interest as small as 1 µm. We 
show that we effectively eliminate chosen bacteria while keeping surrounding 
environment healthy, using the spatial confinement afforded by 2PE light. This 
conference proceedings focuses on one aspect of paper VII and is further 
developed therein. 
Figure 33. (A) MPM images reconstructed into a 3D representation of a Staphylococcus 
epidermidis biofilm stained with SYTO9 (green, stains cells with intact membranes) and PI 
(red, stains cells with compromised membranes). Field of view = 424 x 424 x 90 µm. (B) 
Results of photoinactivation of bacteria with curcumin (λexc = 950 nm). Boxed area and 
arrows demonstrate the region of interest irradiated. (C) Image analysis of image shown in 
B. A thresholding algorithm and 3D surface rendering of the PI-stained cells was 
implemented to demonstrate the specificity of the irradiated region. Imaged used with 
permission from [138]. 
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5.7 Paper VII 
 
Curcumin, and curcumin complexed with HPγCD (“curcumin-CD,” described in 
section 4.3.2), were used for this proof-of-principle investigation in which three 
primary concerns surrounding the study and treatment of biofilms were 
addressed.  
Penetration depth of drug compounds was determined using techniques described 
previously but further optimized with the use of inherently fluorescent bacteria, 
thus providing a control to accurately measure penetration. As seen in figure 34, 
Figure 34. (A) Two photon microscopy images of S. epidermidis biofilms (blue) incubated 
with curcumin in PBS (bottom panel), curcumin-CD complex in PBS (mid panel) and 
control (top panel). Left column shows emission for bacteria only (388 – 493 nm) and right 
panel shows emission for curcumin (543 – 678 nm). Two photon excitation (λ = 950 nm) 
was used. z-stacks range from 60 to 120 µm using a z-step of 1 µm (B) Airyscan 
microscopy images of S. epidermidis biofilms incubated with curcumin or curcumin-CD, 
shown in the green channel. Bacteria are stained with FM4-64 membrane stain (λex/em = 
515/640 nm) shown in the red channel. Emission was collected using a 570-620 nm 
bandpass with a 570 longpass filter combination and 495-550 nm bandpass filter. Images 
used with permission from [14]. 
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curcumin complexed with a penetration enhancer appeared to distribute better 
within the 3D biofilm structure. 
Airyscan confocal microscopy revealed the subcellular uptake of the PS (figure 
34); both curcumin preparations (curcumin in PBS and curcumin-CD) appear to 
localize within bacteria cells.  
In addition, a non-invasive method for monitoring treatment efficacy was 
presented. The biofilms were subjected to photodynamic inactivation (PDI) using 
curcumin and curcumin-CD and viability was measured in real-time using 
LIVE/DEAD fluorescence staining and 3D imaging and analysis (data in [15]). 
Lastly, a novel method for eliminating adherent bacterial cultures was explored 
by using spatially confined 2PE. 800nm near infrared 2PE could excite the PS in 
confined regions as small as 1 µm to selectively eliminate bacteria in only the 
irradiated region while keeping surrounding bacteria healthy, demonstrated in 
figure 35. 
This work presents a novel method for confined killing of bacteria through 2PE 
photoinactivation through proof-of-principle studies; although more experiments 
are required to expand and characterize this technique.  
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A 
Figure 35. Two photon excited (2PE) photodynamic inactivation (PDI) of S. epidermidis 
with curcumin and curcumin-CD. (A) 2PM images collected in z-stacks of 1 µm, where 
“z” represents the height from the surface of the biofilm. Biofilms were irradiated with 2PE 
in the boxed regions only (λexc = 950 nm). Green fluorescence represents intact cells 
(stained with SYTO9), red fluorescence represents membrane-compromised cells (stained 
with propidium iodide). (B) 2PM spectra corresponding to images of PDI with curcumin, 
spectra represent fluorescent signal from STYO9 and PI stains. (C) 2PM spectra 
corresponding to images of PDI with curcumin-CD. Images used with permission from 
[14]. 
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The overall aim of this thesis was to develop biophotonics approaches for 
studying delivery of photopharmaceuticals and antimicrobials to biological 
systems. The approaches developed focused on use of MPM, spectral detection, 
and Airyscan microscopy to monitor delivery and interaction, while the 
pharmaceutical compounds studied have been based on fluorescent-reporting 
nanoparticles designed to release toxic species or carry drug compounds through 
an inclusion complex, as in the case of the cyclodextrins.  
The delivery of fluorescent-reporting photoactivatable compounds was explored 
as a method to monitor potential toxicity in paper I. In addition, the NO 
photoreleasing system could successfully signal release of NO species, but with 
minimal toxicity using 2PE compared to 1PE. This opens new possibilities for 
tracking NO and drug delivery in cells without associated cellular toxicity and 
adds evidence to the theory of the NO cytotoxicity mechanism [139]. While the 
results may support the theory that peroxynitrite is required for NO-mediated 
cytotoxicity, this mechanism is still under debate. Thus, these experiments should 
be further optimized in experimental design as well as repeated with other 
systems.   
The tissue imaging advantages of MPM were employed to monitor nanoparticle 
delivery in skin. A novel approach for non-invasively studying drug release in 
tissue using FRET-reporting nanoparticles was presented. Although, the 
nanoparticle system did not uphold the requirements necessary for quantifiable 
FRET studies, the approach holds promise for tracking drug release in tissues, 
and should be subject to further improvements in future study. 
Nanoparticles expressing inherent luminescence were monitored to determine 
depth of localization in skin using MPM and spectral imaging. It was shown that 
penetration is size-dependent and the particles accumulate primarily in the skin 
furrows (up to 25 µm in depth). Spectral characterization of the nano-systems 
also demonstrated excitation-dependent luminescence; providing evidence of the 
formation of carbon nanodots within the particles developed, in agreement with 
earlier reports [140, 141]. 
An in vitro biofilm model of S. epidermidis was developed for MPM imaging and 
inherently fluorescent strains of S. epidermidis were created for studies of 
compound penetration in biofilms, eliminating the need for external staining. 
With the use of MPM spectral imaging, it was found that positively charged β-
cyclodextrins show improved accumulation within the 3D biofilm structure 
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compared to negative or neutral charged, supported by literature [15]. This 
method provides details regarding how compounds spatially interact with 
biofilms. Future studies should focus on the mechanism of interaction of β-
cyclodextrin within the biofilm, i.e., investigate if it is sequestered by the EPS or 
binding to cells, and if this changes the efficacy of drug delivery.  
Using these same methods, it was also shown that complexation of curcumin 
within cyclodextrin enhances distribution of the compound in the biofilm. To 
answer questions of biofilm viability, a non-invasive diagnostic method for 
monitoring viability as a 3D “map” was presented using LIVE/DEAD staining 
with MPM spectral imaging. Quantification of fluorescence signal within each 
depth layer of biofilms was performed as a complementary approach to traditional 
biological assays in which the 3D information from biofilm bacteria may be lost. 
Curcumin was further monitored for potential toxicity using 2PE PDI, shown for 
the first time in biofilms. It was demonstrated that curcumin-mediated 2PE PDI 
can selectively inactivate confined regions as small as 1x1x1 µm within biofilms. 
This experiment was particularly challenging with the systems used; real-time 
measurements of LIVE/DEAD stained biofilms was time and cost-intensive, thus 
to be studied in detail as a potential translational method, a more systematic 
approach to this experiment should be developed. 
Subcellular localization of two different antimicrobial systems, a β-cyclodextrin-
curcumin complex and a FITC-tagged γ-cyclodextrin, were determined using 
high resolution Airyscan confocal microscopy; in one case it was found that the 
photosensitizer curcumin appears to localize intracellularly in S. epidermidis 
bacteria while γ-cyclodextrin (tagged with FITC for fluorescence tracking) 
appears to localize primarily surrounding the bacteria, perhaps in the EPS. The 
results here are an interesting approach to understanding single-bacteria 
interactions with drug carriers, but complementary biological studies should be 
added for a better understanding. Additionally, image analysis would expand on 
the interpretation of these results.  
The γCD studied for subcellular localization was also monitored for toxicity. The 
γCD was loaded with the antibiotics oxacillin and rifampicin and increased 
efficacy of these two CD-antimicrobial complexed was measured, compared to 
antibiotic alone, in S. epidermidis biofilms, continuing from earlier reports on 
γCD-antibiotic complexes [134]. It was found that the CD-rifampicin complex 
significantly decreased bacterial viability compared to free antibiotic. Combined 
with the results that γCD does not localize subcellularly, this suggests that γCD 
is able to act as a carrier for antibiotics to be more efficiently delivered to bacteria 
in the biofilm format. These results are promising for future work in delivering 
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antibiotics to biofilm infections but should be expanded to further characterize 
the release mechanism of antibiotics from CDs as well as measuring the system 
on different bacterial strains and with different antibiotics for a more robust study. 
In conclusion, this work resulted in multiple findings of importance in 
development of pharmaceutical systems and applications of biophotonics 
techniques to study delivery. But there is more work to be done. Continuing 
research can be done to strengthen these findings, which will be discussed next 
in chapter 7. 
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A large portion of the research presented in this thesis, undertaken in the last four 
years, was focused on method development before any experiments could be 
performed. Thus, future work could be focused on applying the methods that have 
been developed in a more systematic and quantitative perspective.  
Further evidence could help elucidate the mechanism of peroxynitrite and cell 
toxicity in paper I. It was shown that NIR 2PE photorelease of NO may not 
produce the same effect as traditional 1PE photorelease. Although initial studies 
to demonstrate that peroxynitrite may be the underlying cause of NO toxicity, 
supported previously in literature [139], this is still at the hypothesis stage and 
further control studies should be undertaken to answer this. Furthermore, NO 
release was monitored in direct relation to 1PE excitation; measuring NO release 
in cells simultaneous to 2PE excitation would be an important complement to this 
study. This measurement is very challenging in vitro but could be done with the 
use of an additional fluorescence reporter, although the challenge then becomes 
overlap in signal of a potential NO cross-stain and the test compound (CPA). 
In paper II, qualitative monitoring of FRET efficiency did demonstrate proof-of-
concept but to quantitatively measure NO release via FRET efficiency, a new 
nanoparticle system should be developed. The 2PE spectrum of the acceptor 
fluorophore, rhodamine, is broadened compared to 1PE, so creating a FRET pair 
in which the acceptor would not be excited by the donor excitation wavelength is 
a challenge. With a better design, accurate quantitative assessments of resonance 
energy transfer via equation 4 in section 2.1.6 could be performed and potentially 
connected to NO release. 
Further experimentation to elucidate the mechanistic reasoning that positively 
charged cyclodextrins interact better with gram-positive biofilms, as shown in 
paper IV and paper V, should be performed, such as investigations into the 
interaction of CDs and CD-antibiotic complexes with the EPS, biofilm matrix, 
and effects of CDs when loaded with a wider range of antibiotics and applied 
against more challenging bacterial systems such as Staphylococcus aureus and 
gram-negative bacteria. In addition, paper V could be complimented with further 
studies such as measuring the inherent antibiotic effect of γCD; this was 
monitored via MPM imaging but should be measured with a standard biological 
assay, and monitoring the difference in biofilm viability in different z levels of 
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the biofilm when treated with free antibiotic compared to γCD-complexed 
antibiotic. 
In papers VI and VII, spatially confined photodynamic inactivation of bacteria 
with 2PE was performed for the first time. This study could be complimented 
with investigations of the photosensitizer mode of action and toxicity to bacteria 
monitored with comparative biological assays. In addition, feasibility in a 
translational setting is an issue that could be addressed by considering the most 
recent developments in clinical NIR light delivery to complex disease target sites. 
The biggest challenge with this study was monitoring the viability of the biofilm 
in a very confined region. The goal was to demonstrate that bacteria were targeted 
in a very small area, in 3D, but to do this, viability staining was used combined 
with sensitive imaging techniques. To reproduce these results was very cost- and 
time-consuming, thus to make this technique widely available would require 
further optimization. 
In all, this work contributes to the field of biophotonics by developing and 
applying methods for studying the delivery of new photopharmaceuticals and 
antimicrobials to a range of biological systems. It has been shown here that the 
interaction of light with biology can provide information on drug delivery and 
localization, and structural integrity of complicated tissue and biological matter, 
and the information collected was used to characterize novel 
photopharmaceutical and antimicrobial compounds. My understanding of the 
future of the field is that these techniques will be moved towards more 
quantitative measurements. Imaging and spectral detection are useful 
compliments in most in vitro and in vivo studies today, but to use this information 
to measure physiological indicators in-clinic seems to be the next step. This is 
seen in current efforts to move forward in e.g., optical clinical diagnostics [142] 
and fluorescence-guided surgery [143], or in-clinic theragnostic approaches of 
light-emitting and light-excited pharmaceutics [2]. In terms of bacterial 
infections, quickly diagnosing and monitoring infection, with 3D assessment in 
the body, could provide major improvements in treatment [144]. In addition, the 
path forward of photoantimicrobials applied to antibacterial resistant infections 
might also be focused on optical development, i.e. clinical light technology, in 
tandem with pharmaceutical and biophotonics techniques, to produce 
translational research in this relatively new field [145, 146].  
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